A phase 2 trial of SSGJ-705 and SSGJ-612 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07646626 by Shenyang Sunshine Pharmaceutical Co., LTD., with 150 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: SSGJ-705, SSGJ-612 and SSGJ-705 combined with chemotherapy.
Shares SSGJ-705, 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.